M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Treatment of Tumors of the Choroid Plexus Epithelium

Phase 3

Terminated

Conditions: Choroid Plexus Tumors

Interventions: Drug: Carboplatin
Drug: Cyclophosphamide
Drug: Etoposide
Drug: Vincristine
Radiation: Radiation Therapy

First Posted Date: 2007-07-13

Last Posted Date: 2020-02-27

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 2

Registration Number: NCT00500890

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Pain Management Following TRAM Flap for Breast Reconstruction

Not Applicable

Completed

Conditions: Breast Cancer

Interventions: Drug: Saline
Drug: Bupivicaine

First Posted Date: 2007-07-12

Last Posted Date: 2013-10-11

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 61

Registration Number: NCT00500565

Locations: 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States

Tracking of Respiratory-Induced Tumor Motion Using Implanted Fiducials

Not Applicable

Completed

Conditions: Lung Cancer

Interventions: Procedure: CT Scans
Procedure: Implanted markers
Radiation: Radiation Treatment (RT)

First Posted Date: 2007-07-12

Last Posted Date: 2013-02-01

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 10

Registration Number: NCT00500513

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Preoperative and Postoperative Imatinib Mesylate Study in Patients With c-Kit Positive GIST

Phase 2

Completed

Conditions: Gastrointestinal Stromal Tumors

Interventions: Drug: Imatinib Mesylate (Gleevec)

First Posted Date: 2007-07-12

Last Posted Date: 2011-08-08

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 28

Registration Number: NCT00500188

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Intermittent Use of Aerosolized Ribavirin for Treatment of RSV

Phase 4

Completed

Conditions: Hematological Malignancies

Interventions: Drug: Ribavirin

First Posted Date: 2007-07-12

Last Posted Date: 2012-08-01

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 51

Registration Number: NCT00500578

Locations: 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States

Imatinib Mesylate, Busulfan, Fludarabine, and Antithymocyte Globulin for CML Patients

Phase 2

Terminated

Conditions: Leukemia

Interventions: Drug: Imatinib Mesylate
Drug: Fludarabine (Fludara)
Drug: Busulfan
Drug: Antithymocyte Globulin (ATG)
Drug: Tacrolimus
Drug: Methotrexate
Procedure: Donor lymphocyte infusion (DLI)
Procedure: Stem Cell Transplant

First Posted Date: 2007-07-12

Last Posted Date: 2012-04-23

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 42

Registration Number: NCT00499889

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Doxil, Gemcitabine, and Velcade (PS341) in Advanced Cancer Patients

Phase 1

Completed

Conditions: Solid Tumors

Interventions: Drug: Doxil
Drug: Gemcitabine
Drug: Velcade

First Posted Date: 2007-07-12

Last Posted Date: 2013-02-13

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 134

Registration Number: NCT00500422

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Hormonal Ablation, Imatinib Mesylate and Docetaxel for Patients With Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Drug: Docetaxel
Drug: Imatinib Mesylate
Drug: Leuprolide
Drug: Goserelin Acetate

First Posted Date: 2007-07-12

Last Posted Date: 2015-04-28

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 39

Registration Number: NCT00500110

Locations: 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States

Prevalence of Endometrial Abnormalities In Obese Women

Conditions: Obesity

Interventions: Behavioral: Questionnaire

First Posted Date: 2007-07-12

Last Posted Date: 2021-02-25

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 200

Registration Number: NCT00500591

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Effect of Tight Control of Blood Glucose During Hyper-CVAD Chemotherapy For Acute Lymphocytic Leukemia (ALL)

Phase 3

Terminated

Conditions: Leukemia
Lymphoma

Interventions: Drug: Insulin Glargine
Drug: Insulin Aspart

First Posted Date: 2007-07-12

Last Posted Date: 2015-06-03

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 52

Registration Number: NCT00500240

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy